Pseudotumors of the central nervous system

Česká verze

Authors: J. Zámečník ¹; L. Mrázková ²
Authors place of work: Ústav patologie a molekulární medicíny, 2. LF UK a FN Motol, Praha ¹; Klinika zobrazovacích metod, 2. LF UK a FN Motol, Praha ²
Published in the journal: Čes.-slov. Patol., 48, 2012, No. 4, p. 184-189
Category: Přehledový článek

Summary

The histopathological differentiation of the pseudoneoplastic lesions from the tumors of the central nervous system (CNS) is not easy in a proportion of cases and the risk of diagnostic misinterpretation in biopsies of the CNS remains relatively high. Here we discuss selected CNS lesions, which can be easily mistaken for a tumor, particularly in the absence of relevant clinical and neuroradiological data - gliosis, tumefactive demyelination, radionecrosis and focal cortical dysplasia. With the exception of the recently available IDH1 immunohistochemistry, there is a lack of simple and reliable histochemical or molecular markers which could facilitate this differential diagnosis. To avoid a diagnostic error, pathologists have to rely on careful microscopic analysis along with its correlation with clinical data and neuroradiological findings.

Keywords:
pseudotumor – brain biopsy – glioma – gliosis – demyelination – radionecrosis

Zdroje

1. Swain RS, Tihan T, Horvai AE, et al. Inflammatory myofibroblastic tumor of the central nervous system and its relationship to inflammatory pseudotumor. Hum Pathol 2008; 39(3): 410–419.

2. Hausler M, Schaade L, Ramaekers VT, et al. Inflammatory pseudotumors of the central nervous system: report of 3 cases and a literature review. Hum Pathol 2003; 34(3): 253–262.

3. Bertoni F, Unni KK, Dahlin DC, Beabout JW, Onofrio BM. Calcifying pseudoneoplasms of the neural axis. J Neurosurg 1990; 72(1): 42–48.

4. Wiebe S, Munoz DG, Smith S, Lee DH. Meningioangiomatosis. A comprehensive analysis of clinical and laboratory features. Brain 1999; 122 (Pt 4): 709–726.

5. Beressi N, Beressi JP, Cohen R, Modigliani E. Lymphocytic hypophysitis. A review of 145 cases. Ann Med Interne (Paris) 1999; 150(4): 327–341.

6. Prayson RA, Cohen ML. Practical Differential Diagnosis in Surgical Neuropathology. Totowa, NJ: Humana Press; 2000.

7. Yang B, Prayson RA. Expression of Bax, Bcl-2, and P53 in progressive multifocal leukoencephalopathy. Mod Pathol 2000; 13(10): 1115–1120.

8. Cunliffe CH, Fischer I, Monoky D, et al. Intracranial lesions mimicking neoplasms. Arch Pathol Lab Med 2009; 133(1): 101–123.

9. Giese A, Kucinski T, Hagel C, Lohmann F. Intracranial tuberculomas mimicking a malignant disease in an immunocompetent patient. Acta Neurochir (Wien) 2003; 145(6): 513–517.

10. Utsuki S, Oka H, Miyazaki T, et al. Primary central nervous system large B-cell lymphoma with prolific, mixed T-cell and macrophage infiltrates, mimicking multiple sclerosis. Brain Tumor Pathol 2010; 27(1): 59–63.

11. Singh A, Strobos RJ, Singh BM, et al. Steroid-induced remissions in CNS lymphoma. Neurology 1982; 32(11): 1267–1271.

12. Rivera-Zengotita M, Yachnis AT. Gliosis versus glioma?: don’t grade until you know. Adv Anat Pathol 2012; 19(4): 239–249.

13. Colodner KJ, Montana RA, Anthony DC, et al. Proliferative potential of human astrocytes. J Neuropathol Exp Neurol 2005; 64(2): 163–169.

14. Yaziji H, Massarani-Wafai R, Gujrati M, et al. Role of p53 immunohistochemistry in differentiating reactive gliosis from malignant astrocytic lesions. Am J Surg Pathol 1996; 20(9): 1086–1090.

15. Okamoto Y, Di Patre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 2004; 108(1): 49–56.

16. Švajdler M, Rychlý B, Fröhlichová L, et al. Vybrané biomarkery primárnych nádorov centrálneho nervového systému: krátky prehľad. Cesk Patol 2012; 48(2): 65–71.

17. Camelo-Piragua S, Jansen M, Ganguly A, et al. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neuropathol Exp Neurol 2011; 70(2): 110–115.

18. Bourne TD, Elias WJ, Lopes MB, Mandell JW. WT1 is not a reliable marker to distinguish reactive from neoplastic astrocyte populations in the central nervous system. Brain Pathol 2010; 20(6): 1090–1095.

19. Burel-Vandenbos F, Benchetrit M, Miquel C, et al. EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis. J Neurooncol 2011; 102(2): 171–178.

20. Wisniewski T, Goldman JE. Alpha B-crystallin is associated with intermediate filaments in astrocytoma cells. Neurochem Res 1998; 23(3): 385–392.

21. Dinda AK, Sarkar C, Roy S. Rosenthal fibres: an immunohistochemical, ultrastructural and immunoelectron microscopic study. Acta Neuropathol 1990; 79(4): 456–460.

22. Quinlan RA, Brenner M, Goldman JE, Messing A. GFAP and its role in Alexander disease. Exp Cell Res 2007; 313(10): 2077–2087.

23. Johnson AB, Brenner M. Alexander’s disease: clinical, pathologic, and genetic features. J Child Neurol 2003; 18(9): 625–632.

24. Lassmann H. Mechanisms of inflammation induced tissue injury in multiple sclerosis. J Neurol Sci 2008; 274(1–2): 45–47.

25. Barkhof F, Rocca M, Francis G, et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol 2003; 53(6): 718–724.

26. Paty DW, Oger JJ, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988; 38(2): 180–185.

27. Yamada S, Yamada SM, Nakaguchi H, et al. Tumefactive multiple sclerosis requiring emergent biopsy and histological investigation to confirm the diagnosis: a case report. J Med Case Rep 2012; 6(1): 104.

28. Kaeser MA, Scali F, Lanzisera FP, Bub GA, Kettner NW. Tumefactive multiple sclerosis: an uncommon diagnostic challenge. J Chiropr Med 2011; 10(1): 29–35.

29. Annesley-Williams D, Farrell MA, Staunton H, Brett FM. Acute demyelination, neuropathological diagnosis, and clinical evolution. J Neuropathol Exp Neurol 2000; 59(6): 477–489.

30. Sugita Y, Terasaki M, Shigemori M, Sakata K, Morimatsu M. Acute focal demyelinating disease simulating brain tumors: histopathologic guidelines for an accurate diagnosis. Neuropathology 2001; 21(1): 25–31.

31. Zagzag D, Miller DC, Kleinman GM, et al. Demyelinating disease versus tumor in surgical neuropathology. Clues to a correct pathological diagnosis. Am J Surg Pathol 1993; 17(6): 537–545.

32. Lucchinetti CF, Gavrilova RH, Metz I, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 2008; 131(Pt 7): 1759–1775.

33. Fong IW, Toma E. The natural history of progressive multifocal leukoencephalopathy in patients with AIDS. Canadian PML Study Group. Clin Infect Dis 1995; 20(5): 1305–1310.

34. Kodetová D, Jirásek A, Briner J, Fales E. Progresivní multifokální leukoencefalopatie (PML): Morfologické možnosti diagnostiky klasickými metodami a in situ hybridizací. Cesk Patol 1999; 35(1): 5–9.

35. Hoche F, Pfeifenbring S, Vlaho S, et al. Rare brain biopsy findings in a first ADEM-like event of pediatric MS: histopathologic, neuroradiologic and clinical features. J Neural Transm 2011; 118(9): 1311–1317.

36. Gavra M, Boviatsis E, Stavrinou LC, Sakas D. Pitfalls in the diagnosis of a tumefactive demyelinating lesion: A case report. J Med Case Rep 2011; 5: 217.

37. Ball WS, Jr., Prenger EC, Ballard ET. Neurotoxicity of radio/chemotherapy in children: pathologic and MR correlation. AJNR Am J Neuroradiol 1992; 13(2): 761–776.

38. Burger P, Boyko O. The pathology of central nervous system radiation injury. In: Gutin P, Leibel S, Sheline G, eds. Radiation Injury to the Central Nervous System. New York, NY: Raven Press; 1991: 191–208.

39. Nelson DR, Yuh WT, Wen BC, Ryals TJ, Cornell SH. Cerebral necrosis simulating an intraparenchymal tumor. AJNR Am J Neuroradiol 1990; 11(1): 211–212.

40. Marks JE, Wong J. The risk of cerebral radionecrosis in relation to dose, time and fractionation. A follow-up study. Prog Exp Tumor Res 1985; 29: 210–218.

41. Zámečník J. Neuropatologie farmakorezistentní epilepsie - strukturální podklad a mechanismy epileptogeneze. Cesk Patol 2012; 48(2): 76–82.

42. Zámečník J, Homola A, Cicanič M, et al. The extracellular matrix and diffusion barriers in focal cortical dysplasias. Eur J Neurosci 2012; 36(1): 2017–2024.